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Abstract
Aim: A double-blind randomized controlled trial to determine whether dietary sup-
plementation with fruit/vegetable/berry juice powder concentrates, simultaneously
with non-surgical periodontal therapy, improved 2-month treatment outcomes.
Methods: Volunteers with chronic periodontitis were randomly assigned to one of
three groups: fruit/vegetable (FV), fruit/vegetable/berry (FVB) or placebo. Supple-
ments were taken daily during non-surgical debridement and maintenance and out-
comes assessed at 2, 5 and 8 months after completion. Primary outcomes were
mean probing pocket depth (PPD), clinical attachment gain, % sites bleeding on
probing (% BOP) at 2 months. Adherence and plasma b-carotene were determined.
Results: Sixty-one nutritionally replete (by serum biochemistry) volunteers
enrolled and 60 (n = 20 per arm) completed the 2-month review. Clinical out-
comes improved in all groups at 2 months, with additional improvement in PPD
versus placebo for FV (p < 0.03). Gingival crevicular ﬂuid volumes diminished
more in supplement groups than placebo (FVB; p < 0.05) at 2 months, but not at
later times. The % BOP (5 months) and cumulative plaque scores (8 months)
were lowered more in the FV group (p < 0.05).
Conclusions: Adjunctive juice powder concentrates appear to improve initial
pocket depth reductions in nutritionally replete patients, where plasma micronu-
trient bioavailability is attainable. Deﬁnitive multicentre studies in untreated and
treated patients are required to ascertain the clinical signiﬁcance of such changes.
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Periodontitis is a complex chronic
inﬂammatory disease requiring the
emergence of a pathogenic bioﬁlm
whose expression is governed by a
number of host-dependent component
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tive contributions of the various
component causes to disease initia-
tion and/or progression varies from
patient to patient, resulting in a
widely heterogenic clinical pheno-
type. Disease severity and extent also
appear to be inﬂuenced by the same
exposures, in conjunction with local
anatomical features. Tissue destruc-
tion arises largely from a dysregula-
tion of chronic inﬂammatory
processes that the body’s homoeo-
static maintenance systems fail to
resolve, resulting in a failure to elim-
inate pathogenic components of the
subgingival bioﬁlm and a persistence
of chronic non-resolving inﬂamma-
tion (Van Dyke 2008).
Exposure categories believed to
contribute component causes to perio-
dontal inﬂammation include: genetic
(Michalowicz et al. 1991); environ-
mental (e.g. bioﬁlm, stress); lifestyle/
behavioural (e.g. smoking, diet) and
pharmacological (e.g. corticoster-
oids); and “nutrition”, which is inﬂu-
enced by lifestyle, environmental and
genetic exposure categories (Chapple
2009). Evidence is emerging for asso-
ciations between such lifestyle fac-
tors and periodontal inﬂammation
(Bawadi et al. 2011).
Epidemiological studies demon-
strate that a higher intake of fruit
and vegetables (FV) is associated
with a lowered risk of atherogenic
cardiovascular disease (Joshipura
et al. 1999), ischaemic stroke (Joshi-
pura et al. 2001) and mortality
(Knekt et al. 1996, Sauvaget et al.
2003). Diets rich in vegetables and
Vitamin C also appear to associate
positively with better periodontal
health and negatively with periodon-
tal disease progressing more rapidly
in undernourished populations
(Enwonwu et al. 2002). Given the
high prevalence of periodontitis in
the population (moderate disease
prevalence 20–50%; Ko ¨ nig et al.
2010) and its impact upon elevating
plasma biomarkers of systemic inﬂa-
mmation (D’Aiuto et al. 2004a, b), it
appears that periodontal inﬂamma-
tion makes a signiﬁcant contribution
to the systemic inﬂammatory burden.
In recent years, strong evidence
has emerged that diets rich in reﬁned
carbohydrates and saturated fats are
pro-inﬂammatory, whereas those rich
in polyunsaturated fats (ﬁsh oils),
antioxidant micronutrients (fruits,
berries and vegetables) and certain
nuts (cashews) are anti-inﬂammatory
(O’Keefe et al. 2008). Pro-inﬂamma-
tory diets drive oxidative stress
within cells and tissues through meta-
bolic (mitochondrial) and receptor-
mediated pathways (reviewed by
Chapple 2009) and such post-pran-
dial oxidative stress (Sies et al. 2005),
termed “meal induced inﬂammation”
(O’Keefe & Bell 2007) positively cor-
relates with the magnitude (Esposito
et al. 2008) and frequency (Ceriello
et al. 2008) of post-meal surges in
glucose and triglycerides. The latter,
a consequence of the rapid absorp-
tion of glucose and lipids into the
blood stream following intake of die-
tary reﬁned carbohydrate and satu-
rated fats, gives rise to elevations in
plasma levels of CRP and pro-inﬂam-
matory cytokines (Monnier et al.
2006) and oxidative stress (Chapple
2009). Indeed, recent evidence has
demonstrated a signiﬁcant role for
oxidative stress in promoting bone
resorption via activation of certain
transcription factors (FoxOs, which
decreases wnt signalling), modulated
by insulin resistance and increasing
age (reviewed by Galli et al. 2011).
Antioxidant micronutrients combat
such pro-inﬂammatory cascades
through modulation of oxidative
stress by directly scavenging reactive
oxygen species (ROS) and also by
down-regulation of some redox-
sensitive pro-inﬂammatory gene
transcription factors such as nuclear
factor-kappa B and activator protein-
1 while up regulating anti-inﬂamma-
tory gene transcription factors such
as nuclear factor (erythroid-derived
2)-like 2 (Nrf2: reviewed by Chapple
& Matthews 2007). Indeed, adjunc-
tive phytonutrient supplementation
using juice powder concentrates of
fruit, vegetables and berries (FVB)
has been shown to reduce the immedi-
ate impact of a high fat test meal
upon inﬂammatory biomarkers and
to improve ﬂow mediated dilatation
of the brachial artery (Plotnick et al.
2003).
Oxidative stress, deﬁned as an
imbalance between oxidants and
antioxidants in favour of the oxidants,
leading to a disruption of redox sig-
nalling and control and/or molecular
damage (Sies & Jones 2007) is a key
pathological event underpinning
periodontal tissue destruction (Chap-
ple & Matthews 2007, Bullon et al.
2009, Galli et al. 2011). Since the
ﬁrst indirect demonstration of oxida-
tive stress within the periodontal tis-
sues (Chapple et al. 1997), a body of
evidence has accumulated demon-
strating elevated biomarkers of oxi-
dative stress (Sugano et al. 2000,
Takane et al. 2002, Wei et al. 2004,
Panjamurthy et al. 2005, D’Aiuto
et al. 2010) and antioxidant compro-
mise (Chapple et al. 1997, 2002,
Brock et al. 2004, Panjamurthy et al.
2005, D’Aiuto et al. 2010) in peri-
odontitis patients. Recent data from
our own laboratory demonstrated
that the antioxidant depletion mani-
fest locally within the periodontal
tissues appears to be an eﬀect rather
than a cause of the oxidative stress,
which develops during periodontal
inﬂammation (Chapple et al. 2007b,
Grant et al. 2010). Nevertheless, it is
biologically plausible that boosting
the antioxidant micronutritional sta-
tus of patients may have preventive
and/or adjunctive therapeutic bene-
ﬁt, in particular in those patients
who show micronutrient deﬁciency
(Tonetti & Chapple 2011).
The potential impact of diet
upon periodontal inﬂammatory sta-
tus was recently illustrated in a
Swiss study, which found that when
10 adults were placed in a “stone-
age” environment for 4 weeks, with
negligible oral hygiene and diets
were “stone-age” in nature (id est.
low in simple sugars and high in
antioxidant micronutrients, ﬁsh oils
and ﬁbre), they remarkably demon-
strated signiﬁcant decreases in gingi-
val bleeding and probing depths,
despite signiﬁcant increases in pla-
que accumulation (Baumgartner
et al. 2009).
Recent case–control studies have
demonstrated that periodontitis
patients have signiﬁcantly lower
serum antioxidant micronutrient lev-
els than unaﬀected controls (Brock
et al. 2004, Panjamurthy et al. 2005,
Konopka et al. 2007), and also com-
promised gingival crevicular ﬂuid
(GCF) antioxidant status (Chapple
et al. 2002, 2007b, Brock et al.
2004). Non-surgical periodontal ther-
apy has been shown to restore cer-
tain antioxidant components in a
process attributed to reducing levels
of oxidative stress secondary to the
resolution of periodontal inﬂamma-
tion (Chapple et al. 2007b). How-
ever, non-surgical therapy did not
© 2011 John Wiley & Sons A/S
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molecule antioxidant species, gluta-
thione (GSH), although the ratio of
GSH to its oxidized counterpart was
restored, implying at least a restora-
tion of the redox balance within
periodontal cells and tissues follow-
ing successful periodontal therapy
(Grant et al. 2010). Large scale epi-
demiological studies also consistently
support a strong inverse association
between serum antioxidant micro-
nutrient concentrations and periodon-
titis prevalence and severity, in
several diﬀerent populations (Nishada
et al. 2000, Amarasena et al. 2005,
Amaliya et al. 2007, Chapple et al.
2007a, Linden et al. 2009). Jenzsch
et al. (2009) demonstrated that diets
rich in vegetables, fruits, legumes and
dairy products, when employed as
the only intervention, signiﬁcantly
improved pocket depth and gingival
inﬂammation in periodontitis patients
with metabolic syndrome. The
reported data point towards the bio-
logical plausibility of beneﬁcial peri-
odontal outcomes being derived from
phytonutritional interventions of anti-
oxidant micronutrients, acting by
direct scavenging of ROS, and also
by modulation of redox-sensitive
pro-inﬂammatory gene transcription
factors.
There remains a paucity of data
from prospective intervention studies
on the role of nutrition in the patho-
genesis of periodontitis (van der Vel-
den et al. 2011). Speciﬁcally, there
are no reports from placebo-con-
trolled randomized trials on the eﬃ-
cacy of nutritional supplements
upon periodontal outcomes. There-
fore, we hypothesized that:
(a) Daily supplementation with a
primarily antioxidant juice pow-
der phytonutrient (Juice Plus+
®
-FV) would signiﬁcantly improve
treatment outcomes over placebo
supplementation, at 3 months
post-therapy commencement
(2 months post-therapy comple-
tion), when used as an adjunct
to conventional non-surgical
periodontal therapy.
(b) Triple therapy with the above
supplement (Juice Plus+
®-FVB)
would produce additional treat-
ment beneﬁt over dual therapy
(FV) and over placebo.
(c) Improved treatment outcomes
with the supplement will be
maintained at 9 months post-
therapy commencement.
The aim of this preliminary inves-
tigator-led study was to ascertain
whether or not daily dietary supple-
mentation with capsules containing
primarily FVB juice powder concen-
trates (Juice Plus+
®; NSA LLC, Col-
lierville, TN, USA), taken during
standard non-surgical periodontal
therapy (no pre-dosing), improved
clinical outcomes of periodontal
treatment 2 months following com-
pletion of non-surgical therapy
(simultaneous supplementation).
Material and methods
Study ethics and governance
This was an investigator-led, three-
arm, placebo-controlled, double-
blind randomized intervention study
(NCT00952536) and was approved by
South Birmingham Local Research
Ethics Committee (05/Q2707/252),
and research governance was over-
seen by South Birmingham Primary
Care Trust Research Management
and Governance (Project Number –
SouthDent116/742). The study was
conducted in accordance with inter-
national Good Clinical Practice stan-
dards.
Study design and volunteers
Volunteers (n = 61) were recruited
from new patient consultation clinics
by one study team member (P. W.),
and were both non-smokers and
medically healthy by medical history
questionnaire. A rolling recruitment
protocol was adopted and non-
smokers selected, as smoking
impacts upon oxidative stress (Chap-
ple & Matthews 2007) and was
deemed to be a likely confounder of
study outcomes. Volunteers were
aged between 30 and 60 years, either
men or women, and had chronic
periodontitis as deﬁned by a mini-
mum of two sites per quadrant with
pocketing or interproximal attach-
ment loss of >6 mm and one-third
radiographic bone loss. The follow-
ing exclusion criteria were applied:
patients with aggressive disease,
patients with physical or mental dis-
ability, pregnant women, patients
whose medical history may place
them at risk of complications from
periodontal therapy (e.g. need for
antibiotic prophylaxis, Warfarinised
patients), patients taking long-term
antimicrobial or anti-inﬂammatory
drugs, patients unable to swallow
capsules, patients unable to provide
informed consent, current smokers
(or within 5 years), patients taking
regular vitamin supplementation.
The study was designed to exit 60
volunteers at 9 months following
recruitment (8 months following
completion of non-surgical treat-
ment) and was conducted over a 4.5-
year period (2005–2010).
Volunteers were provided with a
detailed information sheet and
allowed 2 weeks to consider their
participation, prior to obtaining
their informed consent and enrol-
ment. As volunteers were enrolled
(by M. M.) they were allocated
sequential study numbers (by K. A.)
and provided with their capsules,
suﬃcient for 3 months.
Randomization was performed by
the study statistician (G. D.), who
was independent of the clinical
study team and site, using a com-
puter-generated program http://
www.randomization.com (volunteer
numbers generated from 001 to 070
to allow for loss of up to 10 partici-
pants). The capsules were supplied in
pre-labelled containers.
Baseline measures were also col-
lected at the enrolment visit, prior to
which volunteers were asked to fast
overnight, not to brush and not to
chew gum or drink within 2 h of
their appointment. Protocol adher-
ence was checked prior to sample
collection, and patients were re-
appointed if necessary. Biological
samples were sequentially collected.
The GCF from three deep sites
( 6 mm) and three shallow sites
( 3 mm) was collected as previ-
ously reported (Chapple et al.
2007b) and deep sites were pooled,
on a volunteer and visit basis, as
were samples from the three shallow
sites. The GCF sampling was fol-
lowed by a venous blood sample,
probing pocket depth (PPD) and
recession measures, bleeding scores,
gingival colour index [Modiﬁed Gin-
gival Index (MGI) – Lobene et al.
1986] and plaque indices (Fig. 1).
Patients then had scaling and root
surface debridement performed on a
quadrant by quadrant basis within
1 month and over four visits. At
© 2011 John Wiley & Sons A/S
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and recorded. Capsule re-supply
occurred at recall visits and patients
were recalled at 2, 5 and 8 months
following completion of the last ses-
sion of instrumentation. At each
recall visit, clinical samples and mea-
surements were repeated and volun-
teers exited the study at the 8-month
recall appointment, when capsule
containers were returned and
counted. Volunteers were also asked
to maintain a supplement diary
recording of how many capsules had
been missed. If further therapy was
required at this stage, as judged by
clinical examination, it was performed
by the same therapist (N. L.-M.), but
outside of the study.
All volunteers completed stan-
dard non-surgical periodontal ther-
apy, which was performed by a
single operator (N. L.-M.; 15 years
experience and MPhil degree in clini-
cal periodontal trials) within 4 weeks
of commencing treatment and all
indices were recorded by a single
GCP-trained examiner (M. M.). Scal-
ing and debridement was performed
using a traditional quadrant by
quadrant protocol, using a single
ultrasonic (Densply CavitronPlus
SPS; Densply UK) device and FSI-
100 inserts, and Gracey curettes
(LM-Dental UK). Treatment was
performed systematically until the
root surfaces were considered suﬃ-
ciently clean, each quadrant taking
30–45 min.
Patients commenced their assigned
capsule supplement at their study en-
rolment study visit, within 1 week of
physical instrumentation commenc-
ing (Fig. 1) and continued supple-
mentation during treatment (1 month)
and also for 8 months of maintenance
(total 9 months of supplementation).
Compliance was checked by capsule
count and also by analysing serum
b-carotene levels. There were three
study arms:
Test 1 – Six capsules daily con-
taining the total equivalent of four
FV capsules, and two placebo cap-
sules during periodontal therapy
and for 8 months thereafter.
Test 2 – Six FVB capsules daily
during periodontal therapy and
for 8 months thereafter.
Control – Six placebo capsules
daily during periodontal therapy
and for 8 months thereafter.
In all three study groups, cap-
sules were taken with food twice
daily (three in the morning, three in
the evening).
Outcome measures
Primary outcome measures were (1)
reductions in PPDs (mean per
patient reduction in PPD), (2) reduc-
tion in percentage sites bleeding on
probing (% BOP) from the marginal
tissues (as a primary outcome mea-
sure of tissue inﬂammation), and (3)
mean increase in clinical attachment
level (CAL) at the 2-month post-
therapy recall visit (3 months post-
therapy commencement). Secondary
outcome measures were reductions
in GCF volume from both deep and
shallow sites, gingival redness (MGI
– Lobene et al. 1986), cumulative
plaque index (Lobene et al. 1982)
and recession. Although not part of
the original protocol, a decision was
Recruit volunteer’s week beginning 16
th September 2005
I
Explana on of Study & answer ques ons
Collec on of Wri en Informed Consent
I
Conﬁrma on of Medical History (Rou ne)
Intra oral examina on & special inves ga ons (Rou ne)
Prepara on of prescrip on for treatment (Rou ne)
I
Volunteer enrolment ( me zero)
Placebo (n = 21) FV (n = 20) FVB (n = 20)
GCF samples
Baseline clinical measures & blood sample
Oral hygiene instruc on
Provision of product from randomisa on sheet & instruc ons
I
Scaling and root debridement of 1
st quadrant
Adherence check
I
As above for 2
nd,3
rd &4
th quadrants
Adherence check
Reinforce oral hygiene at 4
th visit
I
Recall visit 1
(3-months post supplement commencing)
2-months post comple on of 4
th quadrant therapy
Placebo (n = 20) FV (n = 20) FVB (n = 20)
I
Adherence check
GCF samples, blood sample & clinical measures
Reinforce oral hygiene and scale and prophylaxis
I
Recall visit 2 (6-months post supplementa on)
5-months post comple on of 4
th quadrant therapy
Placebo (n = 18) FV (n = 18) FVB (n = 18)
I
Adherence check
GCF samples, blood sample & clinical measures
Reinforce oral hygiene and scale and prophylaxis
I
Recall visit 3 (9-months post supplementa on)
8-months post comple on of 4
th quadrant therapy
Placebo (n = 18) FV (n = 18) FVB (n = 18)
I
Adherence check
GCF samples, blood sample & clinical measures
Reinforce oral hygiene and scale and prophylaxis
I
Exit study. Any further treatment required performed as rou ne
Only volunteers
who sa sﬁed
inclusion criteria
approached –
n = 61agreed
and none
refused.
One volunteer
(Placebo)
withdrawn by
study team &
replaced by
study number
(study team
blinded).
Fig. 1. Study ﬂow chart.
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pocket depth reductions as “number
of residual sites >4 mm”, consistent
with contemporary studies published
subsequent to protocol preparation
(Wennstro ¨ m et al. 2005).
Probing measures were performed
in duplicate at six sites per tooth
(two marginal and four proximal)
with a constant force (UNC CP-15
markings – 0.2 N force) probe and
where diﬀerences between duplicate
measures of greater than 1 mm
arose, a third measure was taken.
The mean of the two closest mea-
sures was used. Mean probing
attachment (derived from pocket
depth + recession), and PPD mea-
sures per subject were calculated at
each examination point (baseline, 2,
5 and 8 months post-therapy). Mar-
ginal bleeding was recorded dichoto-
mously (four sites per tooth, mesial,
distal, mid-facial, mid-lingual) and
expressed as mean percentage sites
bleeding on probing (% BOP) per
subject at each examination point.
Plaque levels were quantiﬁed using a
modiﬁcation of the Quigley-Hein
index (Lobene et al. 1982) and
expressed as a whole mouth total
(cumulative) score per volunteer at
each examination point. The study
visits and procedures are summa-
rized in Fig. 1. Outcomes at the
5- and 8-month recall visits were
considered secondary outcomes, as
pathogenic bioﬁlm changes are
evident at this stage (Quirynen et al.
2005) and may lead to early signs of
recalcitrant disease.
Biological samples collected
Gingival crevicular ﬂuid samples
were collected over 30 s using Perio-
paper
™ (Oraﬂow Inc., Smithtown,
NY, USA) strips from the mesio-
buccal aspects of the three deep and
three shallow molar sites per subject
as previously described (Brock et al.
2004). Volumes were read on a pre-
calibrated Periotron 8000
™ accord-
ing to standard methodologies
(Chapple et al. 1999).
Blood was collected into Vacu-
tainer
™ (NHS supplies, Alfreton,
Derbyshire, UK) tubes for serum
and plasma preparation (vide infra).
Platelet depleted plasma was pre-
pared by centrifugation at 1000 g for
30 min. (4°C). Serum was aliquoted
into cryogenic vials, snap frozen and
stored at  80°C for subsequent anal-
ysis of b-carotene and vitamin E.
For vitamin C assay, 0.75 ml meta-
phosphoric acid (100 g/l) was added
to 0.75 ml plasma to precipitate pro-
teins, prior to storage at  80°C. All
samples were stored in the dark and
kept free from direct sunlight at all
stages of handling.
Test products
The verum test capsules are mar-
keted commercially as Juice Plus+
®
and contain a ﬁne, granular powder,
encapsulated in a size 00 gelatin cap-
sule. The placebo test capsules were
of identical appearance and con-
tained primarily microcrystalline cel-
lulose.
The FV capsule contents con-
sisted primarily of a blended FV
pulp and juice powder concentrate
derived from Acerola cherry, apple,
beet, beetroot, broccoli, cabbage,
carrot, cranberry, dates, garlic, kale,
orange, peach, papaya, parsley, pine-
apple, prune, spinach, sugar beet,
tomato, with Spirulina paciﬁca, Lacto-
bacillus acidophilus, rice bran, oat bran
and Dunaliella salina. These active
ingredients were supplemented to pro-
vide declared totals (per daily dose) of
b-carotene (7.5 mg), vitamin E
(46 mg), vitamin C (200 mg) and folic
acid (400 lg). Although the phytonu-
trient capsules are known to contain
polyphenolic antioxidant micronutri-
ents, these vary according to growing
and harvest conditions and absolute
levels were not analysed.
The FVB capsule contents con-
sisted primarily of a blended fruit,
berry and vegetable pulp and juice
powder concentrate. In addition to
all the components within the FV
capsules, FVB capsules also con-
tained material derived from black-
berry, black currant, blueberry,
bilberry, concord grape, elderberry,
raspberry, red currant, green tea,
ginger root, artichoke leaf, grape
seed extract in addition to arginine,
carnitine and co-Enzyme Q10. These
active ingredients were supplemented
to provide declared totals (per daily
dose) of b-carotene (7.5 mg), vitamin
E (66 mg), vitamin C (222 mg) and
folic acid (640 lg). Small quantities
of anti-caking agents (calcium car-
bonate, magnesium oxide, magne-
sium stearate, silicon dioxide,
cellulose) and thickeners (citrus pec-
tin, guar gum) are added to assist
the manufacture of capsules.
b-Carotene analysis (for adherence)
Adherence to supplement usage was
assessed by residual capsule counts
and a supplement adherence diary at
recall visits and also biochemically
by analysis of serum b-carotene lev-
els. b-carotene was determined by
HPLC using isocratic elution, a
reversed phase column (pKb-100,
250 9 4.6 mm
2; Supelco, Bellefonte,
PA, USA), protected by a guard col-
umn (4.6 9 4.6 mm²) with the same
stationary phase and a Merck-Hit-
achi L-7100 pump connected with
a Merck-Hitachi UV/Vis detector
(Merck-Hitachi, Darmstadt, Germany).
b-carotene was detected at 450 nm and
the concentration calculated from
external calibration curves generated
with original standard compounds
and internal standards as previously
reported (Stahl et al. 1993).
Plasma vitamin E and vitamin C
determination at baseline
These analyses at baseline were per-
formed to assess whether or not any
of the volunteers were vitamin deﬁ-
cient. Alpha-tocopherol was extracted
and detected simultaneously with the
UV/VIS detector set at 292 nm (Poli-
dori et al. 2001). Vitamin C was
determined by HPLC using a Merck-
Hitachi L-6200, a pump connected
with a Merck- Hitachi UV/Vis detec-
tor (Merck-Hitachi) and using a com-
mercially available analytical kit
(Chromsystems Instruments & Chem-
icals GmbH, Munchen, Germany),
run according to manufacturer’s
instructions.
Power calculation and statistical analysis
The reported study was the ﬁrst of
its type to the authors’ knowledge
and therefore a power calculation
based upon mean (±SD) outcomes
from pilot work was not possible for
antioxidant outcomes. However,
using the primary outcome measure
of reduction in PPD and assuming a
mean additional PPD reduction in
the supplement groups of 0.4 mm
(as this has been demonstrated in
pharmacological interventions) over
non-surgical therapy alone, 17 vol-
unteers per treatment group were
© 2011 John Wiley & Sons A/S
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two-sided test of equality of means
at the 0.05 level of signiﬁcance with
80% power. This was based on
accepted mean PPD reductions for
mild to moderate periodontitis of
1 mm (moderate) to 2 mm (deep
sites) with non-surgical therapy, and
also upon data from a previous
study that demonstrated mean PPD
reductions of 1.1 ± 0.4 mm (Chapple
et al. 2007b). The study was pow-
ered to detect diﬀerences between
test and placebo groups only. A
total of 61 volunteers were sequen-
tially recruited.
Statistical analysis was performed
by the study statistician (G. D.) and
utilized analysis of covariance, with
baseline measures employed as the
covariates. Tukey’s Honestly Signiﬁ-
cant Diﬀerence was used to compare
the three groups. Analyses were per-
formed using SAS for Windows, ver-
sion 9.2 (SAS Institute Inc., Cary,
NC, USA). All tests were two-sided
and a result was judged statistically
signiﬁcant if its observed signiﬁcance
level (p-value) was less than 0.05. An
intention-to-treat (ITT) analysis was
performed, employing data from all
subjects regardless of adherence to
treatment. Serum b-carotene concen-
trations were also used as a bio-
chemical measure of adherence and/
or an indirect measure of carotenoid
bioavailability.
Missing data: The primary out-
come measures were taken as part of
standard care during the subjects’
8-month review. There was no rea-
son for missing data to be related to
treatment or outcome, but missing
data were checked for any relation-
ship to treatment assignment. Other-
wise missing values were ignored in
the analyses because they were
deemed to be missing completely at
random.
Code breaking: The code was
retained by the statistician and not
broken until the last patient had
completed their 8-month recall visit,
and all data analysis had been com-
pleted.
Results
Volunteer ﬂow through study
The ﬂow of patients through the
study stages is illustrated in Fig. 1.
Sixty-one patients were enrolled and
sixty completed the 2-month post-
therapy visit, providing primary out-
comes for 20 volunteers in each
study group (FV, FVB and placebo).
Six patients withdrew at the 2-month
post-therapy visit. The reasons for
withdrawal were: capsules too large
to swallow, moved away from area,
diﬃculty attending appointments,
unrelated medical problems, lost to
follow-up for unknown reason. One
patient was withdrawn (placebo
group) as they telephoned to inform
that they were experiencing diﬃculty
swallowing, and although this could
not be attributed to the supplements
as opposed to a respiratory tract
infection, the principal investigator
(I. L. C.) decided to withdraw the
volunteer by telephone and to com-
plete treatment outside of the study.
This last volunteer was replaced with
the 61st enrolee. To ensure groups
remained balanced, whilst at the
same time maintaining the blinding
of the study, the statistician provided
a replacement study number.
Demographical and baseline nutritional
data
The volunteer demographics are
recorded in Table 1, and although
more women were enrolled than
men, the groups were similar with
regard to age and gender. There
were no baseline diﬀerences between
groups in peripheral blood levels of
vitamin C (range = 48–58 lmol/l) and
vitamin E (range = 17–19 lmol/l),
which were within SI reference
ranges (Table 1). Baseline b-carotene
concentrations (range = 0.5–0.7 lmol/l)
were below the low end of one refer-
ence range (Young 1987), but within
another commonly used range (Iver-
son et al. 2007); however, there were
no diﬀerences between the study
groups.
Adherence/bioavailability of b-carotene
The supplement diaries and capsule
counts indicated that protocol adher-
ence had been equivalent in all
groups. Serum b-carotene concentra-
tions increased signiﬁcantly at
2 months in both FV and FVB
groups (FV by 5.4 lmol/l, p < 0.0001;
FVB by 3.5 lmol/l, p < 0.0001), but
there was no change in the placebo
group. The diﬀerences between the
supplement and placebo groups
post-supplementation were signiﬁcant
(p < 0.001) and the increase in
serum b-carotene concentrations was
highest in the FV group (Fig. 2) indi-
cating greater micronutrient bioavail-
ability in this group compared with
the FVB group, which does not
appear to result from between group
diﬀerences in adherence, but might
have impacted upon clinical out-
comes.
Changes in primary outcomes
The improvement in clinical out-
comes in the placebo group was con-
sistent with the literature (Cobb
2002) and statistically signiﬁcant.
This is evident from the statistically
signiﬁcant reduction of sites >4m m
at 2, 5 and 8 months post-therapy
Table 1. Demographical and baseline micronutrient data [mean (lmol/l) ± SD] of the test groups
Test group No. Men Women Age (years) b-carotene*
(0.9–4.6)
†
(0.2–1.6)
‡
Vitamin C
§
(30–110)
†
(23–85)
‡
Vitamin E*
(18–29)
†
(12–42)
‡ Mean ± SD Range
Fruit and vegetable 20 6 (30%) 14 (70%) 48.3 ± 8.4 35–69 0.7 ± 0.45 48.1 ± 16.2 18.3 ± 4.4
Fruit, vegetable and berry 20 8 (40%) 12 (60%) 48.1 ± 7.4 33–58 0.6 ± 0.3 57.4 ± 17.6 18.6 ± 5.9
Placebo 20 7 (35%) 13 (65%) 47.9 ± 6.6 38–60 0.5 ± 0.25 57.9 ± 22.0 17.2 ± 3.2
*serum.
§, plasma.
†SI reference ranges (lmol/l) (Young 1987).
‡SI ranges from Iversen et al. AMA Manual of Style: a guide for authors and editors. 10th Edition, New York, Oxford University Press,
2007.
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Thus, after a single phase of non-
surgical therapy, “closed pockets”
(Wennstro ¨ m et al. 2005) increased in
number from an average of 70% of
sites in all three groups at baseline
to 98% (FV group) and 91% (FVB
and placebo groups).
Other primary outcome measures,
pre- and post-completion of non-sur-
gical scaling and root surface ther-
apy, are illustrated in Fig. 3b–d (and
mean values documented in
Table S1). At 2, 5 and 8 months
post-treatment completion there
were signiﬁcant reductions in mean
PPD compared with baseline, consis-
tent with literature reports for mod-
erate periodontitis (Cobb CM 2002;
van der Weijden & Timmermann
2002) for all three groups
(p < 0.0001). At 2 months, reduc-
tions in PPD were statistically signif-
icantly greater in the FV supplement
group relative to the placebo group
(p < 0.03; Fig. 3b). This was not the
case for the FVB group (p = 0.7;
Fig. 3b). Although the PPD levels in
the FV group remained lower
than the placebo and FVB groups at
5- and 8-month recalls, diﬀerences
were no longer statistically signiﬁ-
cant at these secondary time points.
Signiﬁcant post-treatment CAL
gains were detected at all time
points in both FV (p < 0.05) and
FVB (p < 0.02) supplement groups
(Fig. 3c). In contrast, CAL gains in
the placebo groups were only signiﬁ-
cant over baseline at 5 months.
Despite this, CAL gains within sup-
plement groups over those measured
in the placebo group did not reach
statistical signiﬁcance (p > 0.09).
At all post-treatment reviews, the
percentage of sites bleeding on prob-
ing (% BOP; Fig. 3d) was signiﬁ-
cantly reduced in all three study
groups (p < 0.002). Although the
reduction in % BOP was greatest at
all time points for the supplement
groups, the additional improvement
relative to placebo was only statisti-
cally signiﬁcant at the 5-month sec-
ondary time point for the FV group
(p < 0.05).
Changes in secondary outcomes
Secondary outcomes, pre- and post-
treatment completion, are illustrated
in Fig. 4 (and mean values docu-
mented in Table S2).
Gingival crevicular ﬂuid volumes
at both shallow and deep sites
reduced with time post-therapy
(Fig. 4a and b). Reductions in vol-
ume at shallow sites were small and
changes only reached statistical sig-
niﬁcance at 8 months in the placebo
(p = 0.007) and FVB (p < 0.02)
groups, with supplementation having
no eﬀect diﬀerent to that shown by
the placebo group. In contrast, GCF
volumes at deep sites were signiﬁ-
cantly reduced at all time points in
all groups post-therapy, with reduc-
tions being consistently greater in
supplementation groups (p < 0.002;
Fig. 4b). However, the greater eﬀect
of supplementation on reducing
GCF volume at deep sites was only
signiﬁcant at 2 months for the FVB
group (p < 0.05).
Signiﬁcant reductions in cumula-
tive plaque scores were detected at
all time points post-therapy in all
groups (Fig. 4c; p < 0.03). No diﬀer-
ences were evident between groups
until month 8, when the reduction in
plaque scores relative to baseline
were signiﬁcantly higher in the FV
group (p < 0.05) compared with the
placebo group.
There were progressive improve-
ments in recession and MGI post-
therapy in all three study groups
(Fig. 4d and e; p < 0.001), but no
signiﬁcant diﬀerences in the magni-
tude of improvement between groups
at any time point.
Discussion
The current study is the ﬁrst to
report the impact of providing peri-
odontitis patients with an adjunctive
phytonutrient supplement during
standard mechanical non-surgical
periodontal therapy. We hypothe-
sized that additional clinical beneﬁt
would result from supplementation
with a juice powder concentrate
(FV) and that the triple therapy
(FVB) would provide enhanced out-
comes over the dual supplement
(FV) due to additional polyphenolic
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95% conﬁdence intervals (Tukey’sHSD) for the diﬀerence in changes from baseline to 2-months post-therapy for primary outcomes are:
PPD: FV vs Placebo mean –0.2 (CI –0.33, –0.014)  % BOPFV vs Placebo mean –5.2 (CI –13.1, 2.63)
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Fig. 3. Changes in primary outcomes during the study period (mean ± SD). (a) Sites
>4 mm deep; (b) PPD (mm); (c) CAL (mm); (d) %BOP. Bars represent comparisons
with baseline. Symbols alone represent comparisons with placebo. *p < 0.0001;
■p = 0.002; ●p < 0.01; +p < 0.03; ♦p < 0.05.
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68 Chapple et al.antioxidants. The rationale for such
hypotheses was based upon the sub-
stantial literature base concerning
the eﬃcacy of antioxidant micro-
nutrients in reducing extracellular
oxidative stress, and their intracellu-
lar role in the down-regulation of
redox-regulated pro-inﬂammatory
gene transcription factors (reviewed
by Chapple & Matthews 2007,
Chapple 2009). Statistically signiﬁ-
cant additional reductions in PPD
were seen at the 2-month post-ther-
apy recall visit for FV verses pla-
cebo, providing partial fulﬁlment of
the ﬁrst hypothesis. Therapy employ-
ing the FVB supplement did not,
however, provide signiﬁcantly
improved primary outcomes relative
to the placebo group, despite the
presence of additional polyphenolic
micronutrients within. Hypothesis
two was therefore not fulﬁlled and
nor was hypothesis three, as the ini-
tially greater pocket depth reduction
in the FV group was not sustained
at 8 months post-therapy.
It was surprising not to see simi-
lar additional improvements for the
FVB as the FV group, but this may
be explained by the reduced bio-
availability of micronutrients in this
group as demonstrated by the serum
b-carotene levels (Fig. 2). It may
also be explained by nutrigenetic dif-
ferences between groups, as poly-
morphisms in the BCMO1 gene
(b-carotene 15,15′-monoxygenase)
have been identiﬁed (Leung et al.
2009) which appear to explain, at
least in part, the low conversion
rates of b-carotene to its bioactive
form in many individuals. The atten-
uation in serum b-carotene concen-
trations at 5 and 8 months could
also have arisen due to reduced
adherence to supplementation in the
FVB group; however, this thesis was
not supported by the supplement
diary and capsule count analysis. An
alternative explanation is that micro-
nutrient absorption across the gas-
trointestinal tract wall may have
been lower in the FVB than the FV
group, or that the additional poly-
phenolic compounds within the FVB
supplement antagonized beneﬁcial
activities of other components.
Whatever the explanation, the
plasma b-carotene data demonstrate
reduced bioavailability of some mi-
cronutrients in the FVB group rela-
tive to FV.
Signiﬁcant additional reductions
in percentage sites bleeding on prob-
ing arose for the FV group at
5 months (following the increased
2-month pocket depth reductions).
The cumulative plaque index data
recorded in the supplementation
group are also interesting, as signiﬁ-
cant additional decreases were
observed at the 8-month follow-up
visit for FV verses placebo, 3 months
after the additional improvements in
percentage sites bleeding recorded in
the same group (FV). Although it
could be argued that the improved
plaque index in the supplement
group arose due to better home care/
compliance, this seems unlikely, as
there were no diﬀerences between
groups in plaque indices at 2- and
5-month recalls, where the most sub-
stantial reductions in plaque took
place. An alternative and intriguing
explanation is that additional reduc-
tions in inﬂammation evident at
5 months were reﬂected in the com-
position of the GCF, which in turn
led to a reduced bioﬁlm accumula-
tion. Although this is consistent with
current evidence that the inﬂamma-
tory status of the gingival tissues
inﬂuences plaque bioﬁlm accumula-
tion (Hillam & Hull 1977, Baumgart-
ner et al. 2009) and with current
consensus views on host response/
bioﬁlm inter-relationships (Tonetti &
Chapple 2011), plaque re-growth
studies and those analysing GCF
composition would be necessary to
substantiate such a thesis. A prebi-
otic eﬀect upon bioﬁlm accumulation
is unlikely as capsules were swal-
lowed and nutrients not applied
locally. Any eﬀect therefore would
appear likely to be due to the inﬂu-
ence of an altered systemic (and
downstream local) host response
upon the periodontal bioﬁlm (Marsh
& Devine 2011).
The healing and resolution of
inﬂammation arising from the non-
surgical mechanical therapy alone
(placebo group) was substantial and
consistent with the literature (van
der Weijden & Timmermann 2002),
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Fig. 4. Changes in secondary outcomes during the study period (mean ± SD). (a) Gingival
crevicular ﬂuid (GCF) volumes (ll) – shallow sites; (b) GCF volume (ll) – deep sites; (c)
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the number of closed pockets appar-
ent at 2 months and at subsequent
recalls. Moreover, there were no
baseline diﬀerences between groups
in circulating concentrations of vita-
min E, vitamin C or b-carotene,
all of which were within or close
to the low end of published SI refer-
ence ranges (Young 1987). Taken
together, it is perhaps surprising that
any additional clinical beneﬁt was
achieved in patients who were eﬀec-
tively nutritionally replete and in
whom non-surgical management
alone was highly successful. Some of
those beneﬁts were not retained after
8 months, a ﬁnding that does not
fulﬁl our third hypothesis and which
may be explained by a number of
factors, including a tendency for
recalcitrant disease to develop at this
stage (Quirynen et al. 2005). How-
ever, given that there is a more lim-
ited rationale to the expectation of
improved therapeutic outcomes in
nutritionally replete verses deplete
patients (Schiﬀerle 2009) and that
non-surgical therapy was successful
without adjunctive nutritional sup-
port, it is possible that more sub-
stantial clinical beneﬁts may be
realized from such dietary augmenta-
tion in nutritionally depleted perio-
dontitis patients or in those who do
not have access to dental services for
periodontal therapy. The public
health beneﬁts of such an approach,
in a society where obesity trends are
increasing and diets are decreasing in
quality (Jenzsch et al. 2009) may be
substantial if proven. Indeed, there is
evidence from one intervention study
in patients with metabolic syndrome
that inﬂammatory periodontal out-
come measures improved following a
nutritional intervention (Jenzsch
et al. 2009). Such ﬁndings when
allied to the impact of periodontal
inﬂammation upon systemic inﬂam-
matory status may further impact
upon chronic inﬂammation in the
body in general (Kawashima et al.
2007, Jin et al. 2010).
There are limitations to the cur-
rent study. Firstly, the study may
have lacked the power to detect the
beneﬁcial eﬀects of FV and FVB
because we had no prior data upon
which to base sample size estimates.
Secondly, assessing protocol adher-
ence was diﬃcult, preventing a “per
protocol” analysis. The analysis pre-
sented is an “ITT” analysis, which
assumes that non-adherence will be
random and thus equitable across
the three groups. We did not
attempt to ascertain nutrigenetic
parameters which are likely to dic-
tate “high responders” and “low
responders”, largely because this sci-
ence is in its infancy and the most
appropriate outcome measures are
unknown, with the exception of
recent discoveries in relation to
b-carotene converter status and poly-
morphisms in the BCMO1 gene
(Leung et al. 2009). Thirdly, the high
improvements recorded in the pla-
cebo group from mechanical
debridement alone are likely to have
created a ceiling eﬀect, whereby fur-
ther improvement from adjunctive
therapy is less likely.
We conclude that adjunctive daily
supplementation with an encapsu-
lated FV juice powder concentrate,
during non-surgical periodontal ther-
apy, appears to oﬀer additional initial
pocket depth reductions, and subse-
quent additional improvements in
bleeding on probing and plaque
scores even in high responders to con-
ventional therapy and in those who
are not nutritionally compromised.
However, outcomes seem to depend
upon the serum/plasma micronutrient
concentrations achieved, and this
requires patient adherence and likely
favourable absorption across the
gastrointestinal tract wall. Further
studies are necessary to assess such
approaches in larger and more
diverse populations, employing diﬀer-
ent supplement and therapeutic
regimes. In particular, monotherapy
studies (phytonutrient supplementa-
tion alone) and studies in nutritionally
compromised patients are necessary to
help build a clearer picture of the
clinical impact of antioxidant phy-
tonutrient supplementation upon peri-
odontal and systemic inﬂammatory
status.
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Clinical Relevance
Scientiﬁc rationale for study:
Recent evidence from case–control,
cohort and epidemiological studies
supports an association between
antioxidant micronutrient status
and periodontitis prevalence and
severity. However, there are cur-
rently no data from intervention
studies, performed as blinded ran-
domized controlled trials (RCTs)
reporting upon the eﬃcacy of phy-
tonutritional supplement interven-
tions concurrent with periodontal
treatment upon periodontal out-
comes.
Principal ﬁndings: We report a dou-
ble-blind, placebo-controlled RCT,
employing daily dietary supplemen-
tation with capsules containing pri-
marily FV or FVB juice powder
concentrate as an adjunct during
non-surgical periodontal therapy.
Statistically signiﬁcant adjunctive
clinical beneﬁts were evident at
2 months for PPD reductions in the
FV group and at 5 and 8 months
for the secondary outcomes of %
BOP and % sites with plaque, rela-
tive to placebo.
Practical implications: Micronutri-
ent supplements may impact upon
periodontal therapeutic outcomes,
although the mechanisms of such
adjunctive beneﬁt remain unclear.
Deﬁnitive studies are now war-
ranted employing diﬀerent designs
and accommodating nutrigenetic
considerations to determine the
clinical impact of such therapy.
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